insights_auto
Why is BEAM up 2.31%?
Dive Deeperchevron_right
BEAM:NASDAQ
Beam Therapeutics Inc
$27.02
arrow_upward
+2.31%(+0.61) 1D
$27.40
arrow_upward
+1.41% (+0.38)todayPre-market
Closed: Nov 9, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BEAM...
Open
$26.79
High
$27.39
Low
$25.96
Mkt. cap
2.80B
Avg. vol.
1.86M
Volume
13.05K
52-wk high
$38.26
52-wk low
$20.23
EPS
-$1.00
Beta
2.23
Shares outstanding
103.50M
No. of employees
557
Open
$26.79
High
$27.39
Low
$25.96
Mkt. cap
2.80B
Avg. vol.
1.86M
Volume
13.05K
52-wk high
$38.26
52-wk low
$20.23
EPS
-$1.00
Beta
2.23
Shares outstanding
103.50M
No. of employees
557
News stories
From web sources and news partners
Reuters
·
3 hours ago
S&P 500, Dow futures climb as oil slide lifts sentiment
Yahoo Finance
·
48 minutes ago
Stock market today: Dow, S&P 500, Nasdaq trade mixed ahead of key inflation data
Investor's Business Daily
·
54 minutes ago
Just 3 Of S&P 500's 20 Big Losers Have Recouped Their Nov. 5 Losses
Profile
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks. Wikipedia
About Beam Therapeutics Inc
CEOJohn Evans
Employees557
Founded2017
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitebeamtx.com